Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma

Han Wu; Xin Fei Xu; Jia Qi Zhu; Ming Da Wang; Chao Li; Lei Liang; Hao Xing; Meng Chao Wu; Feng Shen; Dong Sheng Huang; Tian Yang

doi:10.3389/fbioe.2021.695635

Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma

Han Wu, Xin Fei Xu, Jia Qi Zhu, Ming Da Wang, Chao Li, Lei Liang, Hao Xing, Meng Chao Wu, Feng Shen, Dong Sheng Huang, Tian Yang

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, which lacks effective inhibition of progression and metastasis in the advanced clinical stage. Mesoporous silica nanoparticle (MSN)–based cytotoxic or immunoregulatory drug–loading strategies have attracted widespread attention in the recent years. As a representative of mesoporous biomaterials, MSNs have good biological characteristics and immune activation potential and can cooperate with adjuvants against HCC. This review summarizes the possible future development of the field from the perspective of tumor immunity and aims to stimulate the exploration of the immune mechanism of MSN-based therapy. Through this point of view, we hope to develop new clinical immune drugs that can be applied to HCC clinical management in the future.

Original language	English
Article number	695635
Journal	Frontiers in Bioengineering and Biotechnology
Volume	9
DOIs	https://doi.org/10.3389/fbioe.2021.695635
State	Published - 8 Oct 2021
Externally published	Yes

Keywords

hepatocellular carcinoma
immunotherapy
mesoporous silica
nanotechnology
review

Access to Document

10.3389/fbioe.2021.695635

Cite this

@article{4fa7868c67b8465285a4a6df1841661a,

title = "Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma",

abstract = "Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, which lacks effective inhibition of progression and metastasis in the advanced clinical stage. Mesoporous silica nanoparticle (MSN)–based cytotoxic or immunoregulatory drug–loading strategies have attracted widespread attention in the recent years. As a representative of mesoporous biomaterials, MSNs have good biological characteristics and immune activation potential and can cooperate with adjuvants against HCC. This review summarizes the possible future development of the field from the perspective of tumor immunity and aims to stimulate the exploration of the immune mechanism of MSN-based therapy. Through this point of view, we hope to develop new clinical immune drugs that can be applied to HCC clinical management in the future.",

keywords = "hepatocellular carcinoma, immunotherapy, mesoporous silica, nanotechnology, review",

author = "Han Wu and Xu, {Xin Fei} and Zhu, {Jia Qi} and Wang, {Ming Da} and Chao Li and Lei Liang and Hao Xing and Wu, {Meng Chao} and Feng Shen and Huang, {Dong Sheng} and Tian Yang",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Wu, Xu, Zhu, Wang, Li, Liang, Xing, Wu, Shen, Huang and Yang.",

year = "2021",

month = oct,

day = "8",

doi = "10.3389/fbioe.2021.695635",

language = "English",

volume = "9",

journal = "Frontiers in Bioengineering and Biotechnology",

issn = "2296-4185",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma

AU - Wu, Han

AU - Xu, Xin Fei

AU - Zhu, Jia Qi

AU - Wang, Ming Da

AU - Li, Chao

AU - Liang, Lei

AU - Xing, Hao

AU - Wu, Meng Chao

AU - Shen, Feng

AU - Huang, Dong Sheng

AU - Yang, Tian

PY - 2021/10/8

Y1 - 2021/10/8

N2 - Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, which lacks effective inhibition of progression and metastasis in the advanced clinical stage. Mesoporous silica nanoparticle (MSN)–based cytotoxic or immunoregulatory drug–loading strategies have attracted widespread attention in the recent years. As a representative of mesoporous biomaterials, MSNs have good biological characteristics and immune activation potential and can cooperate with adjuvants against HCC. This review summarizes the possible future development of the field from the perspective of tumor immunity and aims to stimulate the exploration of the immune mechanism of MSN-based therapy. Through this point of view, we hope to develop new clinical immune drugs that can be applied to HCC clinical management in the future.

AB - Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, which lacks effective inhibition of progression and metastasis in the advanced clinical stage. Mesoporous silica nanoparticle (MSN)–based cytotoxic or immunoregulatory drug–loading strategies have attracted widespread attention in the recent years. As a representative of mesoporous biomaterials, MSNs have good biological characteristics and immune activation potential and can cooperate with adjuvants against HCC. This review summarizes the possible future development of the field from the perspective of tumor immunity and aims to stimulate the exploration of the immune mechanism of MSN-based therapy. Through this point of view, we hope to develop new clinical immune drugs that can be applied to HCC clinical management in the future.

KW - hepatocellular carcinoma

KW - immunotherapy

KW - mesoporous silica

KW - nanotechnology

KW - review

UR - http://www.scopus.com/inward/record.url?scp=85117701780&partnerID=8YFLogxK

U2 - 10.3389/fbioe.2021.695635

DO - 10.3389/fbioe.2021.695635

M3 - Review article

AN - SCOPUS:85117701780

SN - 2296-4185

VL - 9

JO - Frontiers in Bioengineering and Biotechnology

JF - Frontiers in Bioengineering and Biotechnology

M1 - 695635

ER -

Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this